IL97053A - תכשירי רוקחות המכילים אזאפירונים לטיפול בהפרעות נשימה תרדמתיות - Google Patents
תכשירי רוקחות המכילים אזאפירונים לטיפול בהפרעות נשימה תרדמתיותInfo
- Publication number
- IL97053A IL97053A IL9705391A IL9705391A IL97053A IL 97053 A IL97053 A IL 97053A IL 9705391 A IL9705391 A IL 9705391A IL 9705391 A IL9705391 A IL 9705391A IL 97053 A IL97053 A IL 97053A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- formula
- sleep
- Prior art date
Links
- 201000002859 sleep apnea Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 claims 1
- HCVRCHQFYYZPHT-UHFFFAOYSA-N 8-[4-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCNCC2OC3=CC=CC=C3OC2)C(=O)CC21CCCC2 HCVRCHQFYYZPHT-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000647 gepirone Drugs 0.000 claims 1
- 229950003599 ipsapirone Drugs 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 20
- 229960002495 buspirone Drugs 0.000 description 15
- 208000008784 apnea Diseases 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229960001768 buspirone hydrochloride Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 239000004089 psychotropic agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000034972 Sudden Infant Death Diseases 0.000 description 2
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001730 monoaminergic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000003169 respiratory stimulant agent Substances 0.000 description 2
- 229940066293 respiratory stimulants Drugs 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- -1 8-[4-[4-(l-pyrimidinyl)-l-piperazinyl]butyl]-8-azaspiro[4, 5]decane-7,9-dione hydrochloride Chemical compound 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067775 Upper airway obstruction Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940060734 buspirone hydrochloride 5 mg Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47882090A | 1990-02-12 | 1990-02-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL97053A0 IL97053A0 (en) | 1992-03-29 |
| IL97053A true IL97053A (he) | 1995-10-31 |
Family
ID=23901492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9705391A IL97053A (he) | 1990-02-12 | 1991-01-25 | תכשירי רוקחות המכילים אזאפירונים לטיפול בהפרעות נשימה תרדמתיות |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0442424B1 (he) |
| JP (1) | JP3227578B2 (he) |
| KR (1) | KR910015301A (he) |
| AT (1) | ATE115858T1 (he) |
| CA (1) | CA2036039A1 (he) |
| CY (1) | CY1990A (he) |
| DE (1) | DE69106008T2 (he) |
| DK (1) | DK0442424T3 (he) |
| ES (1) | ES2068407T3 (he) |
| HK (1) | HK19797A (he) |
| HU (1) | HUT56497A (he) |
| IL (1) | IL97053A (he) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620993A (en) * | 1995-06-07 | 1997-04-15 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| US5661163A (en) * | 1995-06-07 | 1997-08-26 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| US7160898B2 (en) | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| DE69931042T2 (de) | 1998-02-27 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois, Urbana | Stoffe mit serotoninartiger wirkung zur behandlung der schlafapnoe |
| DE19953625A1 (de) * | 1999-11-08 | 2001-05-17 | Richter Diethelm Wolfgang | Verwendung von 5HT-1A Serotonin Rezeptor Agonisten zur Behandlung von genetischen oder funktionellen Atemrhythmusstörungen |
| JP2008524332A (ja) | 2004-12-20 | 2008-07-10 | コレジウム ファーマシューティカル， インク． | 睡眠傷害のための医薬組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4612312A (en) * | 1984-07-30 | 1986-09-16 | Merrell Dow Pharmaceuticals Inc. | Glutarimide antianxiety and antihypertensive agents |
-
1991
- 1991-01-25 IL IL9705391A patent/IL97053A/he not_active IP Right Cessation
- 1991-02-08 CA CA002036039A patent/CA2036039A1/en not_active Abandoned
- 1991-02-11 HU HU91437A patent/HUT56497A/hu unknown
- 1991-02-11 ES ES91101889T patent/ES2068407T3/es not_active Expired - Lifetime
- 1991-02-11 KR KR1019910002289A patent/KR910015301A/ko not_active Withdrawn
- 1991-02-11 DK DK91101889.3T patent/DK0442424T3/da active
- 1991-02-11 DE DE69106008T patent/DE69106008T2/de not_active Expired - Lifetime
- 1991-02-11 AT AT91101889T patent/ATE115858T1/de not_active IP Right Cessation
- 1991-02-11 EP EP91101889A patent/EP0442424B1/en not_active Expired - Lifetime
- 1991-02-12 JP JP03902991A patent/JP3227578B2/ja not_active Expired - Lifetime
-
1997
- 1997-02-20 HK HK19797A patent/HK19797A/en not_active IP Right Cessation
- 1997-09-05 CY CY199097A patent/CY1990A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3227578B2 (ja) | 2001-11-12 |
| JPH0517358A (ja) | 1993-01-26 |
| HUT56497A (en) | 1991-09-30 |
| ATE115858T1 (de) | 1995-01-15 |
| CY1990A (en) | 1997-09-05 |
| DE69106008T2 (de) | 1995-05-04 |
| ES2068407T3 (es) | 1995-04-16 |
| HU910437D0 (en) | 1991-08-28 |
| IL97053A0 (en) | 1992-03-29 |
| EP0442424B1 (en) | 1994-12-21 |
| EP0442424A1 (en) | 1991-08-21 |
| DE69106008D1 (de) | 1995-02-02 |
| HK19797A (en) | 1997-02-20 |
| DK0442424T3 (da) | 1995-02-20 |
| CA2036039A1 (en) | 1991-08-13 |
| KR910015301A (ko) | 1991-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6432956B1 (en) | Method for treatment of sleep apneas | |
| US4640921A (en) | Treatment of sexual dysfunction with buspirone | |
| US20220151975A1 (en) | Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients | |
| US20060039867A1 (en) | Method for treating sleep-related breathing disorders with setiptiline | |
| HU202108B (en) | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol | |
| IL97054A (he) | תכשירי רוקחות המכילים בוספירון לטיפול בהפרעות נשימה תרדמתיות | |
| TW201929859A (zh) | 夜間頻尿治療劑 | |
| IL97053A (he) | תכשירי רוקחות המכילים אזאפירונים לטיפול בהפרעות נשימה תרדמתיות | |
| UA76254C2 (en) | Use of desoxypeganine for treating clinical depression | |
| JPH02209808A (ja) | 物質嗜癖の治療法 | |
| JP2005325070A (ja) | 睡眠改善剤 | |
| Kolski et al. | The Use of Theophylline Clearance in Pediatric Status Asthmaticus: I. Interpatient and Intrapatient Theophylline Clearance Variability | |
| HK1005016B (en) | Use of buspirone in sleep apneas | |
| WO2000006163A1 (en) | Improved method for treatment of sleep-related respiratory disorders | |
| Lear et al. | Comparative studies of tranquilizers used in anesthesia | |
| JPH04282313A (ja) | 血圧降下剤 | |
| EP2482658B1 (en) | Methods and compositions for treatment of raynaud's phenomenon | |
| Wallace | Preanesthetic medication without narcotics: use of promethazine and a sympathomimetic agent in 5,500 patients | |
| JPH0219318A (ja) | 疝痛及び生歯に対する治療 | |
| JPH0692303B2 (ja) | 恐慌障害の軽減に対するゲピロン | |
| JPH10330265A (ja) | 肝疾患治療剤 | |
| JPH0341024A (ja) | 気管支喘息治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |